人神经生长因子治疗糖尿病性多发性神经病的随机双盲研究  

A Randomized Controlled Clinical Study of Human Nerve Growth Factor for Treating Diabetic Polyneuropathy

作　　者：张云云[1] 苏雅茹[1] 杨莉芹[1] 蒋雨平[1] 

机构地区：[1]复旦大学附属华山医院神经内科,200040

出　　处：《中国临床神经科学》2003年第1期67-70,共4页Chinese Journal of Clinical Neurosciences

摘　　要：目的:观察人神经生长因子(hNGF)治疗糖尿病性多发性神经病(DPN)的有效性及安全性。方法:采用双盲随机对照研究,48例DPN病人随机分为2组:hNGF组24例,每日给予hNGF 4 mL(1000 u),肌注:对照组 24例,每日给予安慰剂 4 mL,肌注,疗程均为12周。结果:hNGF组治疗12周后,患者MDNS和自觉感觉障碍有效率分别为73.83％和83.33％,明显高于安慰剂组。治疗结束后4及12周,其有效率仍显著高于对照组。治疗期间未发现严重不良反应。结论:hNGF治疗DPN有效且安全。Aim:To observe the effectiveness and reliability of human nerve growth factor (hNGF) for the treatment of diabetic polyneuropathy (DPN) .Methods: Forty-eight patients sufferring from DPN were studied in a double blindness randomized controlled clinical trial. The 48 patients were devided randomizedly into two groups: the hNGF group and the control group, each had 24 patients. The hNGF group was treated with hNGF (1000 u·4 ml-1 ,im,qd)for 12 weeks, and the controls were given placebo(4 ml,im,qd) .Results: After 12 weeks of treatment, the effectiveness rates concerning MNDS and sensory disability in the hNGF group were 73.83% and 83.33% respectively,both were significantly higher than those of the control group. The effectiveness rates of the hNGF group remained higher than those of the control group after hNGF had been withdr awn for 4 and 12 weeks. No severe side-effect was found in the treatment period. Conclusion: Human nerve growth factor was effective and safe for the treatment of DPN.

关 键 词：人神经生长因子 糖尿病性多发性神经病 双盲研究 

分 类 号：R587.205[医药卫生—内分泌]